2017 ACVIM Forum Research Abstract Program

nd 28. Almost one-third of the cats (12/40; 29.3%; 95% CI: 18.0-45.6) shed parvovirus DNA during the post-vaccination period. Parvovirus DNA was detectable up to 28 days after immunization. Parvovirus DNA-shedding was significantly associated with a lack of protective pre-vaccination antibody titers (P = 0.016; odds-ratio (OR): 6.44; 95% CI: 1.44-28.89) and with post-vaccination titer increases (P = 0.029; OR: 5.00; 95% CI: 1.17-21.39). Vaccinated cats can shed of parvovirus DNA at least up to 4 weeks after vaccination and shedding occurs more commonly in cats without protective titers. Post-vaccinal shedding thus can interfere with diagnosis in recently vaccinated cats that are presented with clinical signs suspicious for of panleukopenia. Feline herpesvirus 1 (FHV-1) is the most common feline infectious disease in cats, with over 90% of cats housed in group settings being infected. Liposome-TLR ligand complexes (LTLC) have been shown in mice to enhance innate immunity and induce non-specific protection against both viral and bacterial diseases. A new formulation of LTLC to be used as a mucosal immune stimulant (MucosImmune) has been shown to be safe and capable of stimulating local immunity in cats. The objectives of this study were to determine whether MucosImmune administered prior to FHV-1 experimental inoculation or at the first signs of clinical illness post-inoculation in kittens could lessen clinical signs and shedding of FHV-1 when compared to untreated controls.